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Abstract 
Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally-timed 
puberty but occurs at an abnormally early age.  Most cases of CPP are seen in girls, in whom it is usually idiopathic.  
In contrast, ~50% of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical 
and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and significant 
compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold standard for 
the treatment of CPP is with GnRH analogs (GnRHa).  Numerous preparations with a range of delivery systems and 
durations of action are commercially available.  While outcomes of patients treated for CPP have generally been 
favorable, more research about psychological aspects, optimal monitoring and the long-term effects of all forms of 
GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional 
investigation.  
Key points: 
- Molecular genetic etiologies of CPP are beginning to be elucidated.  
- Evaluation of CPP should be based on a combination of clinical and biochemical factors, as each parameter has 
specific limitations. 
- GnRHa are the gold standard of treatment for CPP 
GnRHa provide sustained high concentrations of GnRH resulting in down-regulation of the hypothalamic-pituitary-
gonadal (HPG) axis 
Multiple formulations of GnRHa exist.  Although minor differences in gonadotropin levels are observed, all 
available GnRHa appear to be equally effective in terms of clinical parameters. 
-Long-term outcomes of children treated with GnRHa for CPP are reassuring as regards fertility, BMI and bone 
mineral density (BMD). 
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1. Introduction 
Central precocious puberty (CPP) refers to premature activation of the hypothalamic-pituitary-gonadal (HPG) axis 
resulting in early development of secondary sexual characteristics.  Although the exact threshold defining “normal” 
pubertal timing has been disputed, commonly used cutoffs to define CPP are 8 years of age for females (7.5 years 
for Hispanics and African Americans) and 9 years of age for males[1].  The earliest clinical manifestation of central 
puberty in girls is usually breast development (thelarche), followed by pubic hair (pubarche).  The pubertal growth 
spurt typically occurs during Tanner stage II-III, with the first menstrual period, known as menarche, usually 
occurring at Tanner stage IV.  In boys, the initial clinical sign of central puberty will be testicular enlargement, and 
the pubertal growth spurt happens later than in girls[2, 3]. 
Although the precise mechanisms triggering the onset of puberty are unclear, the earliest known biochemical change 
during puberty is the increased production of kisspeptin in the hypothalamus. While kisspeptin itself has several 
proposed stimulatory and inhibitory signals which are not yet clearly elucidated, it has been shown that increased 
kisspeptin production results in increased gonadotropin releasing hormone (GnRH) release.  Thus, a rise in 
kisspeptin is widely acknowledged as the seminal event which initiates HPG axis activation during puberty[2].  
Inhibition of the GnRH pulse generator decreases first during sleep, resulting in the increase of nighttime LH pulse 
amplitude during early and mid-puberty.  As puberty progresses, LH pulse amplitude increases during daytime hours 
as well, and estrogen and testosterone levels rise accordingly. 
2. Etiology 
CPP, for unknown reasons, is found predominantly in girls.  In an observational study of the incidence of CPP in 
Spain, females were approximately ten times more likely to be affected than males[4], and other sources cite a 
female to male ratio as high as 20:1[5].  In addition, the etiology of CPP differs between genders.  While the 
majority of girls will have idiopathic CPP, boys are more likely to have a pathological source[1, 6].  Risk factors for 
CPP include a history of international adoption as well as congenital or acquired CNS insults such as hypothalamic 
hamartoma, septo-optic dysplasia, tumor, trauma, infection or ischemia.  Several genetic syndromes, including 
neurofibromatosis type 1, tuberous sclerosis, and Sturge-Weber syndrome are associated with CPP[2].  Apart from 
recognized genetic syndromes, anywhere from 5.2-27.5% of cases have been reported to be familial[7, 8].   
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Specific genetic causes of CPP have been described relatively recently.  A substitution mutation in the G-protein 
coupled kisspeptin receptor gene KISS1R (formerly known as GPR54) was found in a patient with CPP and was 
associated with delayed degradation of the receptor-ligand complex within the cell membrane.  This was further 
linked to an extended period of downstream signaling, postulated to result in increased amplitude of GnRH 
pulsatility[9].  An additional KISS1R polymorphism in the promoter region has been described in Chinese girls with 
CPP, though a detailed knowledge of whether or how this variant impacts the expression or function of the gene is 
as of yet unknown[10]. 
A mutation in KISS1, encoding the ligand kisspeptin, has also been described within an amino-terminal sequence 
associated with protein degradation[11].  The mutated ligand-receptor complex similarly demonstrates a resistance 
to degradation.  However, the low population frequency associated with this mutation suggests that it is a relatively 
uncommon cause of CPP. 
More recently, ten separate heterozygous mutations in MKRN3, encoding makorin RING-finger protein 3, have been 
found in association with both sporadic and familial CPP[12-14].  MKRN3 is a paternally expressed imprinted gene 
located within the region typically affected in Prader-Willi syndrome. Although the exact function of MKRN3 in 
humans is yet unknown, studies in mice have illustrated that mkrn3 mRNA is expressed in the hypothalamic arcuate 
nucleus, and that decline of mkrn3 expression is temporally correlated with the rise of kiss1 expression.  Other 
studies postulate that down-regulation of MKRN3 is permissive for increased GnRH pulses during puberty[13]. 
Thus, deficiency of this protein would be expected to result in a loss of inhibition of HPG axis activation.  These 
mutations are thought to result in loss-of-function of the abnormal gene product.  In familial cases, all affected 
subjects inherited mutations from their fathers.  Interestingly, there was an almost equal gender distribution of CPP 
among affected family members[12].   
Other molecular defects have been identified with less clear or weaker associations.  These include single-nucleotide 
polymorphisms (SNPs) in the FSHβ gene and LHβ gene, though the resulting molecular mechanisms which cause 
CPP have not been identified[15].  Mutations in the Y1 subtype receptor for neuropeptide Y (NPY) could 
theoretically cause precocious puberty as NPY is thought to be an inhibitor of pulsatile GnRH secretion.  However, 
the only currently described mutation has not correlated well with an effect on function or with CPP[16].  Additional 
studies have investigated genes involved in hypothalamic hamartomas, and have identified several with increased 
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expression in patients with CPP[17].  LIN28B, postulated to have a role in determining the timing of pubertal 
development, has also been proposed as a genetic target in CPP.  However, the exact role in humans is not yet clear.  
In addition, studies have been contradictory, and no clinically significant mutations have yet been observed causing 
a functional deficit at a molecular level[18, 19]. 
3. Diagnosis 
3.1 Clinical Features 
On initial examination of the child with CPP, bilateral testicular enlargement (≥4 cc in volume) will be apparent in 
males, in contrast to patients with peripheral forms of precocious puberty.  Girls usually present with both breast 
development and pubic hair, in contrast to non-pathological entities such as premature thelarche or premature 
adrenarche.  Other signs of pathologic precocious puberty include a rapid tempo of progression and linear growth 
acceleration. Bone age will typically be advanced, though this is certainly not exclusive to CPP and may be seen to a 
milder degree in numerous other conditions[2].   
3.2 Biochemical Features 
A GnRH stimulation test has long been considered the gold standard for the diagnosis of CPP.  However, lack of 
availability of synthetic GnRH in the US has led to the use of GnRHa for this purpose instead.  While precise cut-
offs are difficult to establish, a peak stimulated LH of >~8 mIU/mL after GnRH and >~5 IU/L after GnRHa are 
considered indicative of CPP[2, 20]. An LH/FSH ratio of ≥2 is also consistent with CPP. However, results should 
always be interpreted in light of the specific assay performed and sensitivity limits available.  An alternative 
diagnostic approach has been the measurement of basal ultrasensitive (US) LH which is typically <0.3 IU/L in 
prepubertal children. However, basal US LH is often prepubertal in early CPP and thus may be falsely reassuring[1]. 
Measurement of basal or stimulated sex steroids, while never sufficient alone, can be helpful in the evaluation of 
suspected CPP. This is particularly true of testosterone, whereas random estradiol levels are often unmeasurable 
even when advanced pubertal development is present. Even if the laboratory evaluation is unremarkable, patients 
should continue to be monitored over time and retested as indicated if clinical suspicion is high[2, 1, 20]. 
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4. Imaging 
Pelvic ultrasound has been found to be a useful adjunct to support the diagnosis of CPP over other forms of puberty 
in girls, especially in equivocal situations.  Uterine and ovarian dimensions have a stronger association with bone 
age than with chronologic age, and are correlated with CPP up to age eight[21].  While proposed cutoffs for uterine 
and ovarian volumes exist, these have been somewhat variable, and other studies suggest considerable overlap 
between patients with and without CPP, making reliable parameters difficult to establish.  For those who present for 
evaluation after age eight, ultrasound parameters become even more difficult to interpret, as there is even greater 
overlap in uterine and ovarian dimensions between prepubertal and early pubertal girls. [21-24].  The finding of 
small ovarian follicles on pelvic ultrasounds is normal even in prepubertal girls[25].  Clinicians should further keep 
in mind that ultrasound results may be technician dependent. 
The role of a brain MRI in the evaluation of patients with CPP has been debated.  Boys are more likely to have a 
pathologic cause, making diagnostic imaging for intracranial pathology an essential tool in their evaluation[6].  
However, controversy exists regarding recommendations in girls.  When female CPP patients without neurological 
symptoms are screened with an MRI, the incidence of positive findings is approximately 15%[26, 27].  However, 
some of the abnormalities found may be incidental and unrelated to the CPP. In one study, 86% of 182 girls had 
normal MRIs, 11% had mild abnormalities believed to be unrelated to CPP, and 3% had hamartomas, leading the 
authors to conclude that routine screening was not indicated in this population, particularly in girls older than age 
6[26].  This is in contrast to a prior study of 67 girls, in whom 6 of 10 with MRI findings had hamartomas, while the 
remainder were diagnosed with astrocytoma, teratoma, arachnoid cyst, and pineal cyst.  Three of 10 had lesions 
requiring surgical intervention, leading the authors to conclude that MRI should be part of the routine evaluation in 
CPP regardless of age[27].  Investigations into clinical and biochemical features of patients with intracranial 
pathology have suggested that younger age of onset, more rapid tempo, and higher levels of sex steroids or 
gonadotropins are predictive features. However, these overlap to such an extent that no specific cutoff has been 
identified that can be used to determine whether or not to obtain an MRI in any individual patient. For this reason, 
many institutions include a brain MRI as a universal part of the evaluation in all children diagnosed with CPP[26-
29]. 
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5. Treatment 
The primary goal of CPP treatment is to preserve final adult height.  However, it should be recognized that some 
patients will have a non-progressive or slowly progressive form of CPP, and these patients can achieve a normal 
adult height without any intervention[20].  Therefore, a period of observation is usually appropriate prior to starting 
treatment.    In patients who do show progression of CPP, there is significant variability in the degree of height 
gained after discontinuation of treatment, even among patients with the same bone age[30-32].  Numerous studies 
have demonstrated that the greatest gain in final height is achieved in girls with onset of puberty before 6 years of 
age, although girls with onset between 6-8 years may still reap some benefit from treatment.  In contrast, girls ≥ age 
8 have not been found to benefit from intervention in terms of height. Thus, treatment in this age group is usually 
not indicated.  An additional issue is that outcomes of treatment are typically defined as the difference between 
predicted adult height at baseline and actual height achieved. Unfortunately, height prediction methods are 
notoriously flawed[33], and have often been found to over-predict height in the setting of early puberty.  Therefore, 
it is impossible to predict the precise amount of additional height that will be gained by an individual patient as a 
result of putting puberty on hold. While preliminary evidence suggests that electronic methods of bone age 
assessment may be more accurate, there is minimal information available thus far about their use in precocious 
puberty [34].  Evidence regarding treatment benefit in males is more limited as they comprise a relatively small 
proportion of patients with CPP.  Existing data suggest a significant improvement in final height after treatment of 
CPP in boys[35], though the same measurement and prediction limitations exist. 
Concerns about psychosocial functioning are often used as a justification for treatment of CPP. However, existing 
data regarding the psychological aspects of CPP are limited and inconsistent. Insufficient controls and 
methodological problems render many studies difficult to interpret, compounded by the use of several different 
assessments which make comparisons difficult.  Current data do not consistently support problems in regards to 
body image, self-esteem, or sexual behavior in patients with CPP.  Differences, where found, tend to be modest and 
suggest that patients with CPP may engage in psychosexual behaviors only slightly earlier than children with on-
time puberty.  The prevalence of psychopathology does not seem to differ from the general population[36].  
Similarly, one study of girls with CPP and their mothers at the time of diagnosis found no difference in 
psychological distress as compared to girls with early normal puberty, even prior to treatment[37].  At this point, 
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there is no consensus regarding whether CPP is associated with psychological distress and/or whether treatment 
ameliorates these problems, and more data in this area are needed[20].   
GnRHa are well established as standard of care for the treatment of CPP worldwide. While numerous delivery 
systems and routes of administration exist, depot intramuscular injections or sustained release preparations have 
been the most widely used.  These drugs are believed to work by providing a steady concentration of GnRH activity 
instead of the pulsatile variation in levels characteristic of native GnRH release which results in a paradoxical down-
regulation and suppression of the HPG axis.  Monthly depot leuprolide acetate has been the most common form of 
injection therapy used in the US.  Although extended release 3-monthly depot leuprolide preparations have been 
available in Europe and elsewhere for many years, they have been approved by the FDA only recently, and are 
available in 11.25 mg and 30 mg dosage forms. Although patients on 11.25 mg 3-monthly injections have 
consistently been shown to have higher stimulated LH and FSH levels compared to patients receiving 7.5 mg 
monthly injections or 22.5 mg 3-monthly injections, this has not been accompanied by a significant difference in sex 
steroid levels or clinical parameters[38, 39].  Additional information about these preparations has been derived from 
a phase III open-label study involving patients receiving 3-month depot leuprolide acetate at 11.25 mg and 30 mg 
doses for 36 months[40].  Of 72 patients, only 2 discontinued therapy prior to 36 months due to treatment failure, 
while 20 discontinued therapy to undergo age-appropriate puberty and 24 continued to receive 3-month depot 
leuprolide for the full study period.  As in previous studies, LH escape was seen in a minority of patients on 
stimulation testing, but this did not correlate with clinical features suggesting lack of suppression.  Thus, 3-monthly 
depot leuprolide seems to be both safe and effective for long-term use[38-40]. 
Adverse effects are similar for 1- and 3-month depot injections and include local reactions and pain at the injection 
site.  Sterile abscess formation has been reported after long-acting injection formulations.  Although children who 
experience sterile abscess formation from long-acting preparations have subsequently been treated successfully with 
daily leuprolide, there are reported cases in the adult literature of resistance to GnRHa following sterile 
abscesses[41]. 
A popular alternative approach to depot GnRHa injections is the histrelin implant, which was approved by the FDA 
in 2007. This non-biodegradable implant is made of a flexible hydrogel containing 50 mg of the potent GnRHa 
histrelin and is placed subcutaneously usually in the inner aspect of the upper arm.  The initial histrelin implant was 
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first developed for the treatment of metastatic prostate cancer, where it was found to successfully suppress LH and 
testosterone levels for up to one year.  The implant was later reformulated to release histrelin at a higher dose of 65 
mcg/day for use in children with CPP.  An initial pilot study in 11 girls previously treated with depot triptorelin 
showed satisfactory maintenance of LH and FSH suppression on stimulation tests.  This was accompanied by 
clinical evidence of pubertal suppression including regression of breast development, decrease in growth velocity, 
and decline in bone age advancement over 15 months.  In addition to satisfactory clinical benefit, parents reported 
less discomfort and lifestyle interference overall compared to monthly injections[42]. Following this initial report, a 
phase III study in 36 patients with CPP demonstrated profound suppression of the HPG axis within one month of 
implantation whether subjects were naïve or previously treated with a GnRHa[43]. The long-term extension phase of 
this study has now been completed, and demonstrated significant improvements in predicted adult height after up to 
6 years of sequential annual histrelin implants[44].  Reassuringly, BMI z-scores remained normal throughout the 
treatment interval.  
A significant refinement of the histrelin implant as a therapeutic option has been the recognition that a single 
implant lasts at least two years. Given the known rate of release of 65 mcg of histrelin per day, a 50 mg implant 
should theoretically last two years. That this is indeed the case was demonstrated in a prospective study in 33 
children with CPP in whom a single implant was left in place for two years. Peak stimulated LH levels at 12 and 24 
months were equivalent and clinical indices of CPP progressively improved. Use of a single implant for two years 
has the potential to significantly decrease costs and numbers of surgical procedures in children treated with this 
modality[45].   
The most common adverse event associated with the histrelin implant is breakage and/or difficulty with localization 
of the device. These events occur only during explantation and have been noted to take place in 15-39% of 
procedures, with a higher likelihood of breakage when the implant is left in place for 2 years[44-47]. Additional 
adverse events reported include local reactions which are for the most part minor and self-limited.  Sterile abscess 
formation[41], keloids[44], site infection[45] and implant extrusion[42] have rarely been reported.  Placement and 
removal of the implant requires a minor surgical procedure.  This is typically accomplished in an outpatient setting 
using local anesthesia with the addition of conscious sedation if necessary[47].  In rare cases of difficulty with 
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implant localization, ultrasound has proved to be a useful modality. Characteristics of the most frequently used 
GnRHa in the United States are summarized in the Table. 
 
6. Adjunctive treatments 
6.1 Non-aromatizable anabolic steroids 
Oxandrolone has been used to improve growth in patients for other indications.  The exact mechanism has not been 
elucidated, but a stimulatory effect on the growth plate has been postulated.  A small nonrandomized study of 10 
patients receiving oxandrolone in addition to GnRHa for severe deceleration of growth velocity during treatment for 
CPP suggested that this combination might improve adult height compared with GnRHa alone.  However, larger 
randomized studies have not been performed[48]. 
6.2 Growth hormone 
Small and nonrandomized studies demonstrate a significant improvement in final adult height over pre-treated 
predicted adult height in patients treated with GnRHa and growth hormone (GH), as compared to patients treated 
with GnRHa alone.  However, larger randomized studies are currently lacking and routine use of GH in this setting 
is not recommended[49]. 
6.3 Aromatase inhibitors 
Aromatase inhibitors have the potential to attenuate estrogenic effects on skeletal maturation and delay epiphyseal 
fusion.  A small randomized study suggested slower bone age advancement and improved adult height in Chinese 
boys with CPP receiving letrozole[50].  However, in general experience with these compounds in CPP is very 
limited. 
7. Monitoring 
Children who are being treated for CPP should receive regular follow up during which pubertal progression or 
suppression can be followed and documented. Tanner staging, determination of growth velocity and assessment of 
skeletal maturation via bone age radiographs are all important indices of suppression. Whether laboratory testing 
should be routinely included during follow-up is controversial.  While several different strategies for biochemical 
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testing exist, no gold standard for how best to monitor children undergoing treatment for CPP has been established. 
A GnRH- or leuprolide-stimulated peak LH should be <4 IU/L in adequately suppressed children, and random 
serum gonadotropin levels should theoretically be in the prepubertal range (US LH <0.3 IU/L).  However, random 
US LH levels have been noted to be elevated above pre-pubertal levels in children who are well-suppressed on 
GnRHa therapy across all forms of treatment, including the histrelin implant[51, 52].  Therefore, the utility of 
measuring random LH levels in children undergoing treatment for CPP is highly questionable.  
8. Resumption of native HPG axis  
In studies following patients beyond discontinuation of treatment, the mean time from cessation of injectable depot 
GnRHa to menses has been found to be 1.5 +/- 0.5 years. Some studies have found a slightly shorter time to menses 
in girls who experienced menarche before treatment than in those who did not.  Although less is known about boys, 
existing data suggest that clinicians can expect advancement of Tanner stage within 6 months of discontinuation of 
treatment[52].   
Because use of the histrelin implant is more recent, data are somewhat more limited but thus far seem to indicate 
similar results, with the average time from explantation to menarche being 12.75 (95% CI 9.6-15.9) months, with a 
range of 2-36 months.  Likewise, in males, resumption of pubertal progression was seen on examination within one 
year.  A negative trend has been noted between total duration of GnRHa therapy and time to menarche, whereas age 
at explantation and time to menarche were significantly inversely correlated[53]. 
9. Outcomes 
Girls with CPP have been found to have a higher BMI compared to their peers at diagnosis.  However, this 
observation is confounded by the natural increase in BMI during puberty.  Indeed, some authors have found that 
while BMI increases in general during treatment, overall BMI SDS score does not change.  When BMI is evaluated 
after GnRHa treatment has been completed, there does not appear to be an adverse effect of treatment on BMI in 
girls with CPP, nor does there appear to be a large impact of CPP itself on BMI at adult height[31, 54, 55]. 
Results regarding the incidence of PCOS in GnRHa treated patients has been quite variable and contradictory, with 
some authors finding markedly increased rates of PCOS and other authors finding little or no difference.  These 
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results are even more difficult to interpret as multiple criteria for the diagnosis of PCOS exist.  Currently no 
consensus exists on whether CPP or treatment with GnRHa results in increased risk for PCOS[2, 54, 56].  
Although BMD has been seen to be slightly reduced during treatment in girls, these changes do not appear to be 
sustained.  This decrease is thought to be secondary to suppression of ovarian function.  However, after treatment is 
discontinued and ovarian activity resumes, BMD is regained so that girls are not significantly different from their 
peers without CPP by evaluation at adult height[31]. 
10. Reproductive function and fertility 
Limited information exists regarding long-term effects of treatment for CPP on endocrine and reproductive function.  
In one study of 49 females receiving monthly depot leuprolide, 20 were followed to adulthood (18 to 26 years).  Of 
these, 80% reported regular menstrual cycles.  Seven of 20 women reported a total of 12 pregnancies, with 6 live 
births, 5 spontaneous or elective terminations, 1 ongoing pregnancy, and no reports of stillbirth[52].  Though 
achievement of short-term treatment goals and resumption of puberty seems similar in girls treated with 3-monthly 
leuprolide and the histrelin implant, it remains to be seen whether similar long term results can be expected.  In 
addition, long-term data are notably lacking for all forms of treatment with regards to fertility and endocrine 
function beyond the third decade as well as timing of menopause. 
11. Future directions 
Although multiple preparations now exist for GnRHa treatment of CPP, further options are under investigation or 
may be considered.  A 6-month formulation of triptorelin, for example, is currently under investigation, providing 
the potential for even less frequent dosing for those who do not wish to undergo a procedure for the histrelin implant 
[57]. 
Other targets for therapy could also be considered.  Because GnRH agonists work by stimulation of receptors 
leading to desensitization, there is an initial period of increased stimulation leading to an LH flare that sometimes 
precipitates vaginal bleeding in girls with advanced pubertal development before suppression takes place.  A GnRH-
antagonist, however, would theoretically forgo this initial phase by disrupting LH pulsatility without an initial flare.  
Kisspeptin agonists and antagonists, by acting upstream of GnRH, would be expected to have similar effects to 
GnRH agonist and antagonist therapies, respectively.  However, since kisspeptin analogs would not work directly at 
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the gonadotropin receptor, they would have the additional theoretical benefit of interrupting pulsatile GnRH and 
gonadotropin secretion without lowering gonadotropin release below basal secretory levels.  Therefore, sex steroid 
levels under treatment with these agents could be expected to more closely mimic normal physiology [58].  Though 
use of kisspeptin antagonists in humans has not yet been studied, animal studies suggest that kisspeptin analogs are 
able to cross the blood-brain barrier and suppress puberty [58]. 
Because existing biochemical markers can be unreliable, monitoring of treatment is also a worthwhile area of 
research.  Markers under investigation include free alpha-subunit (FAS), which rises with suppression of the HPG 
axis.  Though GnRHa levels decrease gradually with discontinuation of depot intramuscular injections, FAS levels 
are seen to acutely decrease within days of histrelin implant removal, preceding LH, FSH, and estradiol rise by 
weeks.  In one case, elevated FAS levels beyond the expected time period corresponded with retained histrelin 
implant fragments, and fell only after all fragments had been removed, highlighting its utility as a target for 
relatively rapid assessment of HPG axis recovery.  A short “rebound” elevation of FAS can be seen in patients 3-8 
weeks after histrelin implant removal.  This effect is short-lived and self-limited, although the reasons for it are 
unclear [59].  
12. Conclusion 
CPP is seen most often in girls and is associated with a multitude of conditions.  A substantial proportion (over a 
quarter) of cases are familial, and genetic causes have begun to be elucidated.  The diagnosis is based on a 
combination of clinical and biochemical factors.  Treatment with a GnRHa provides the greatest potential benefit for 
patients who are younger at the time of onset of CPP.  Multiple treatment options are available, and more recent 
options have the benefit of less frequent dosing, with the potential for improved compliance.  Though several 
adjunctive treatments have been proposed, evidence supporting these treatments is generally sparse in CPP and thus 
cannot be recommended for routine use.  Biochemical markers, bone age, and growth velocity should be followed 
during treatment to ensure efficacy.  Available evidence shows that GnRHa are safe and effective and long-term 
data suggest that reproductive function is satisfactory after discontinuation of treatment. However, long-term data, 
particularly as regards the newer formulations, are still lacking. Continued pharmacologic and molecular genetic 
investigation and rigorously conducted prospective studies will continue to enhance knowledge and optimize 
treatment in children with CPP. 
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Table: Characteristics of the most frequently prescribed GnRHa for the treatment of CPP  
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Admin. Frequency Dose Adverse effects Advantages Disadvantages 
Leuprolide 
acetate 
 
IM Monthly 7.5 mg 
11.25 mg 
15 mg 
Local reactions 
Pain at injection site 
Sterile abscess 
 
 Frequent injections 
Three-monthly 11.25 mg 
30 mg 
Less frequent 
dosing 
 
Triptorelin 
(only 
available in 
Europe) 
IM Monthly 3.75 mg  
 
Frequent injections 
Three-monthly 11.25 mg Less frequent 
dosing 
 
Histrelin 
Implant 
 
SQ 1-2 years 50 mg implants, 
65 mcg/d 
Discomfort at implant 
site 
Local reactions 
Sterile abscess 
Implant extrusion 
Infrequent 
replacement 
Minimal 
opportunity for 
noncompliance 
Conscious or general 
sedation may be 
required 
Implant breakage makes 
removal difficult 
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